United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

United States - English - NLM (National Library of Medicine)

carilion materials management - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

Canada - English - Health Canada

teva canada limited - etidronate disodium; calcium (calcium carbonate) - kit - 400mg; 500mg - etidronate disodium 400mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors

Canada - English - Health Canada

teva canada limited - calcium (calcium carbonate); etidronate disodium - kit - 500mg; 400mg - calcium (calcium carbonate) 500mg; etidronate disodium 400mg - bone resorption inhibitors

Canada - English - Health Canada

teva canada limited - etidronate disodium; calcium (calcium carbonate) - tablet - 400mg; 500mg - etidronate disodium 400mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors

Canada - English - Health Canada

cobalt pharmaceuticals company - etidronate disodium; calcium (calcium carbonate) - tablet - 400mg; 500mg - etidronate disodium 400mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors

Canada - English - Health Canada

sanis health inc - etidronate disodium; calcium (calcium carbonate) - tablet - 400mg; 500mg - etidronate disodium 400mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors

Canada - English - Health Canada

teva canada limited - etidronate disodium - tablet - 200mg - etidronate disodium 200mg - bone resorption inhibitors

Canada - English - Health Canada

teva canada limited - etidronate disodium - tablet - 400mg - etidronate disodium 400mg - bone resorption inhibitors

Canada - English - Health Canada

cobalt pharmaceuticals company - etidronate disodium - tablet - 200mg - etidronate disodium 200mg - bone resorption inhibitors